Nesiritide是重组人脑钠肽,国外多项前瞻性临床研究证实它能较传统静脉治疗药物短期内迅速改善急性失代偿心力衰竭患者的血流动力学状况和症状,从而成为现代心力衰竭治疗的一种新药。但汇总分析调查其安全性发现,可增加短期病死率和肾功能损害的危险性,提示重组人脑钠肽的短期高效并不能代替长期安全性。是否能成为失代偿心力衰竭治疗新的一线用药,需要以病死率为终点事件的大规模前瞻性随机双盲对照研究提供循证医学依据。 Nesiritide is a recombinant human brain natriuretic peptide, a number of prospective clinical studies abroad confirmed that it can be more rapidly than the traditional intravenous drugs in the short term rapid improvement in patients with acute decompensated HF hemodynamic status and symptoms, and thus become a modern heart failure treatment A new drug. However, a pooled analysis to investigate the safety findings may increase the risk of short-term mortality and renal impairment, suggesting that the short-term high efficacy of recombinant human brain natriuretic peptide does not replace long-term safety. Whether or not it can become a new first-line agent for the treatment of decompensated heart failure requires an evidence-based medical basis for a large prospective, randomized, double-blind, controlled study of mortality.